# Menarini / Stemline

Source: https://onco.cc/companies/menarini/  
OnCo record `menarini` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Menarini is the private Italian pharma that commercialises the first oral SERD, elacestrant.

## Summary

Menarini, the private Italian pharmaceutical company based in Florence, commercialises the first oral SERD, elacestrant, through its Stemline oncology unit. Elacestrant, sold as Orserdu, is used in oestrogen-receptor-positive, HER2-negative breast cancer, and tagraxofusp, sold as Elzonris, treats blastic plasmacytoid dendritic cell neoplasm. OnCo links it to HR-positive, HER2-negative breast cancer and to BPDCN, and to both drug records. Whether the first oral SERD keeps its position as newer oral SERDs and degraders reach the market is the open question for Menarini's oncology business. Elacestrant has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Florence
- Type: pharma
- Website: https://www.menarini.com

## Sources

- Official website: https://www.menarini.com

## Connected records

- fronts: [Hormonal Therapy](https://onco.cc/fronts/hormonal/)
- drugs: [Elacestrant](https://onco.cc/drugs/elacestrant/), [Tagraxofusp](https://onco.cc/drugs/tagraxofusp/)
- trials: [A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer](https://onco.cc/trials/nct07766018/), [A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence](https://onco.cc/trials/nct06492616/), [A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy](https://onco.cc/trials/nct06456463/), [ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study](https://onco.cc/trials/nct05596409/), [Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer](https://onco.cc/trials/nct05563220/), [Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer](https://onco.cc/trials/nct05386108/)
- cancers: [Blastic plasmacytoid dendritic cell neoplasm (BPDCN)](https://onco.cc/cancers/bpdcn/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- companies: [Menarini Silicon Biosystems](https://onco.cc/companies/menarini-silicon-biosystems/)

---
JSON: https://onco.cc/api/v1/entities/menarini.json